Genmab — Januar 2016
-
-
Jeps.
-
Blogbuster drømmer om at Arzerra hyhed kan få Genmab over 900!
-
Arzerra kan blive et hit i MS. Novartis har betalt dyrt for Arzerra pga MS
-
Flere analytikere har vist nævnt at der er grund til at være positiv over for Arzerra i MS.
-
Ja det er rigtigt Helge
-
Nordea spar peak sales for Arzerra i MS på USD 2,5 til 3 milliarder (halvdelen af hvad man forventer Roches Ocrelizumab skal sælge)
-
spar = spar
-
spar = spår for poker
-

-
Genmab vinder informationspris
Finansforeningen tildeler Genmab Spcialprisen ved den årlige prisuddeling, som hædrer god kommunikation til de finansielle markeder.
(medwatch.dk)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
-(ofatumumab)-til-forlaenget-behandling-af-recidiverende-eller-progressiv-CLL